Search

everythinglearnresearchcommunity

for

Search:↓

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Pulsed electric field treatment may help the immune system fight liver tumors.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

The treatment combination is effective and generally safe for lung cancer.

New treatments for alopecia areata may target specific immune cells and pathways involved in hair loss.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.

A patient's grey hair regained color during treatment with adalimumab.

Resveratrol-loaded nanoparticles show promise for lung cancer treatment.

Upadacitinib effectively treats pyoderma gangrenosum.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.

Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

Topical calcitriol may reduce hair loss from chemotherapy at higher doses.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Immune therapy for cancer can cause hair loss scars in some patients.

Prurigo nodularis is hard to diagnose and treat, but new biologics offer hope for better management.

Rituximab can cause skin issues, but baricitinib may help improve them.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.